Skyhawk Doses First U.S. Patients in Huntington’s Trial
Boston, Massachusetts, USA, November 5, 2026 Skyhawk Therapeutics, Inc. has announced that the first patients in the United States...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine solid tumors targeted therapy
Boston, Massachusetts, USA, November 5, 2026 Skyhawk Therapeutics, Inc. has announced that the first patients in the United States...
Philadelphia, Pennsylvania and Boston, Massachusetts — October 30, 2026 Latus Bio, Inc. announced new preclinical findings from four poster...
LEXINGTON, Mass. and AMSTERDAM September 29, 2026 — uniQure N.V. announced additional data from ongoing Phase 1/2 studies of...
PALO ALTO, Calif., September 2, 2026 BridgeBio Pharma, Inc. announced plans to present new clinical data on the impact...
LEXINGTON, Mass. and AMSTERDAM, September 2, 2026 uniQure N.V. announced the submission of a Biologics License Application (BLA) to...
NEEDHAM, Mass., Aug. 3, 2026 Candel Therapeutics, Inc. announced that new data from its Phase 3 clinical program evaluating...
CARLSBAD, Calif., Aug. 3, 2026 Design Therapeutics, Inc. reported second-quarter 2026 financial results while providing key clinical updates across...
PARSIPPANY, N.J. and TEL AVIV, Israel, June 5, 2026 Teva Pharmaceuticals announced new real-world data demonstrating that treatment with...
PHILADELPHIA & BOSTON, April 28, 2026 Latus Bio, Inc. has announced new preclinical and computational data supporting its investigational...
AMSTERDAM, BOSTON, and SEATTLE – Sept. 18, 2025 (cGxP.wire) – VectorY Therapeutics, a biotechnology company pioneering vectorized antibody therapies...
